Skip to main content
Skip to main content
Back to Grand Rounds
Grand RoundsWeekly Evidence Brief

Internal Medicine

Edition

30-Second Takeaway

  • Routine ADRD screening of asymptomatic older adults did not improve caregiver or patient outcomes over 2 years.
  • Prediabetes—especially with obesity or in younger adults—meaningfully increases 5-year ASCVD risk and merits earlier, intensive prevention.
  • Digital, plant-based, and dialysis-delivery interventions modestly shift outcomes, with effect sizes sensitive to implementation details.

Week ending April 25, 2026

Risk, Prevention, and Monitoring Across the Care Continuum

Routine ADRD screening in primary care did not benefit family caregivers

JAMA INTERNAL MEDICINEApr 21, 2026

This multisite RCT randomized 1,808 older adult–family dyads to dementia screening (with or without facilitated follow-up) versus no screening in primary care. Only 5.1% of patients screened positive, and more than one-third of those assigned to follow-up declined diagnostic assessment. At 24 months, SF-36 physical and mental component scores did not differ between combined screening groups and no-screening controls. Caregiver preparedness, caregiving self-efficacy, and depression or anxiety also showed no improvement with screening, and no clear psychological harms emerged.

Prediabetes independently elevated 5-year ASCVD risk, especially in young and obese adults

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGYApr 20, 2026

This Kaiser Permanente cohort included 1,358,882 adults aged 18–90 years without prior ASCVD or diabetes; 50.7% had prediabetes at baseline. Over 4.1 years’ mean follow-up, prediabetes conferred a 21% higher adjusted ASCVD risk versus normoglycemia (HR 1.21; 95% CI 1.18–1.25). Relative risk was greatest in adults aged 18–34 years (HR 1.54; 95% CI 1.18–2.02), identifying a particularly vulnerable group. Prediabetes with obesity carried higher 5-year ASCVD risk (HR 1.32) than prediabetes without obesity (HR 1.22) versus those with neither condition.

US use of nonstatin lipid-lowering therapies increased from 2019 to 2024

JAMA CARDIOLOGYApr 22, 2026

This cross-sectional study examined national trends in prescribing nonstatin lipid-lowering agents from 2019 to 2024 compared with statins. It characterizes real-world uptake of ezetimibe, PCSK9 inhibitors, and other nonstatins in contemporary US practice. The analysis highlights how clinicians are adding nonstatins to, or substituting them for, statins in ASCVD prevention and treatment. These patterns can help identify where nonstatin use aligns—or misaligns—with guideline-directed lipid management.

Adaptive mHealth program modestly reduced gestational weight gain in overweight and obese patients

JAMA NETWORK OPENApr 21, 2026

This cluster-randomized trial enrolled 1,265 pregnant patients with BMI 25.0–<40.0 receiving care in an integrated health system. The intervention combined clinician motivational interviewing with an app delivering automated feedback, connected devices, education, and stepped lifestyle coaching. Weekly gestational weight gain was lower with the intervention versus standard care (0.25 vs 0.28 kg/week; mean difference −0.03 kg/week; 95% CI −0.05 to −0.01). Total gestational weight gain was also reduced (9.7 vs 10.6 kg; mean difference −0.87 kg; 95% CI −1.40 to −0.34).

References

Numbered in order of appearance. Click any reference to view details.

Additional Reads

Optional additional studies from this edition.

Edition context

Clinical signal

  • Detection alone is not sufficient; screening and monitoring must demonstrably improve patient or caregiver-centered outcomes to justify routine adoption.
  • Metabolic and dietary risk modification retains large leverage even after cardiometabolic disease is established, reinforcing lifestyle counseling as core therapy.
  • Real-world implementation choices—device type, treatment time, coaching intensity—substantially shape both clinical outcomes and financial sustainability.